Medios Ag · XETR:ILM1
Medios — Q3 2025 Earnings Presentation
30 slides from Medios's earnings presentation, Nov 11, 2025
Slide 1: Q3/9M 2025 Results
Q3/9M 2025 Results Matthias Gaertner, CEO Falk Neukirch, CFO November 11, 2025
Slide 2: Executive summary
1 Executive summary 2 Financial overview 3 Guidance 2025 4 Appendix “We are creating the leading European Specialty Pharma platform to treat diseases optimally with individualized medicine.” Matthias Gärtner, CEO Medios AG 2
Slide 3: Highlights 9M 2025
Executive summary Highlights 9M 2025 9M 2025: Overall, solid financials • Revenue up by 9.2% to €1.5bn (Q3 2025: record revenue of €538m) Financials • Disproportionate EBITDA pre increase to €70.4m (+26.1%) leading to an EBITDA pre margin expansion of 4.6%; 5.1% organic EBITDA pre growth driven by a
Slide 4: QoQ – Revenue and EBITDA pre growth
Executive summary QoQ – Revenue and EBITDA pre growth Revenue (€m) EBITDA pre¹ (€m) 538 507 24.6 24.0 490 493 483 485 23.2 23.1 23.3 431 422 441 456 451 17.2 16.1 15.0 15.1 14.1 14.3 5.0 4.8 4.8 4.6 4.5 3.5 3.3 3.5 3.2 3.3 3.6 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2023 20
Slide 5: YoY 9M 2025: Strong EBITDA pre margin improvement
Executive summary YoY 9M 2025: Strong EBITDA pre margin improvement Revenue in €m EBITDA pre¹ in €m 9.2% 26.1% x 4.6% 70.4 4.0% 1,401 1,530 55.8 EBITDA pre 4.6% margin 4.0% 9M 2024 9M 2025 9M 2024 9M 2025 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortizat
Slide 6: Advanced Therapies (AT) & Personalized Cancer Vaccines (PCV)
Executive summary Advanced Therapies (AT) & Personalized Cancer Vaccines (PCV) Global Market Advanced Therapies Study phases3 Cell therapies $~217bn1 Unmodified or genetically modified cells 5.965 2.563 930 2.472 to replace diseased cells total studies completed terminated active 37 Gene therapies:
Slide 7: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2025, strategy 4 Appendix 7
Slide 8: 9M 2025 – Solid Group financials
Financial overview 9M 2025 – Solid Group financials In € million 9M 2025 9M 2024 ∆ in % Comments Revenue 1,530.0 1,400.5 9.2% Revenue growth of 9.2% driven by inorganic growth of IB and Gross profit1 151.5 107.3 41.3% organic growth of all other operational segments, mainly PS gross margin in % 9.9%
Slide 9: 9M 2025 – Revenue growth driven by International Business
Financial overview 9M 2025 – Revenue growth driven by International Business YoY Revenue in €m 9M 24 Organic Inorganic 9M 25 Comments Pharmaceutical Supply (PS) 1,191.2 48.3 1,239.5 • Inorganic growth attributable to Ceban (IB) Patient-Specific Therapies (PST) 161.6 4.4 166.0 • Organic growth mainly
Slide 10: 9M 2025 – Strong EBITDA pre growth mainly due to IB
Financial overview 9M 2025 – Strong EBITDA pre growth mainly due to IB YoY EBITDA pre1 in €m 9M 24 Organic Inorganic 9M 25 Comments Pharmaceutical Supply (PS) 37.0 1.8 38.8 • Significant organic growth of EBITDA pre by 5.1% driven by PS, PST and IB Patient-Specific Therapies (PST) 16.7 1.4 18.1 • Ce
Slide 11: 9M 2025 – EBITDA pre posted strong growth
Financial overview 9M 2025 – EBITDA pre posted strong growth Pharmaceutical Patient-specific International Services IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' consolidation YoY in € million 9M 25 9M 24 9M 25 9M 24 9M 25 9M 24 9M 25 9M 24 9M 25 9M 24 9M 25 9M 24 Segment revenue – extern. 1,
Slide 12: Financing Structure
Financial overview Financing Structure • New Syndicate loan concluded in Nov 2024 : €225m, consisting of • term loan of €125m, term: 5 yrs, annual redemption €25m starting March 25 and • Revolving credit facility (RCF) €100m (step-up option €50m), term 5 (+1 +1) yrs • Covenant based margin grid • Ne
Slide 13: Guidance 2025, strategy
1 Executive summary 2 Financial overview 3 Guidance 2025, strategy 4 Appendix “Medios delivers the best quality – reliably, competently and fast. These are key criteria for the optimal care of our patients.” 13
Slide 14: Disproportionate EBITDA pre increase expected
Guidance 2025 Disproportionate EBITDA pre increase expected Revenue (€bn) EBITDA pre1(€m) + 6.0% ~2.0 + 21.5% ~96 1.9 79 Margin ~4.8 (%) 4.2 2024 2025E* 2024 2025E* 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization; EBITDA pre is adjusted for special
Slide 15: THANK YOU!
THANK YOU!
Slide 16: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2025, strategy 4 Appendix “I am passionate about working for Medios because patient care is at the center of what we do.” 16
Slide 17: Successful AGM 2025 – Selected agenda items
Appendix Successful AGM 2025 – Selected agenda items Approval of adjusted Compensation system for the Executive Board • Realignment of the Short-Term Incentive (STI) New financial KPI: Operational cash flow • Objective: stronger focus on operational performance indicators • Promotion of efficiency,
Slide 18: ESG highlights 2025
Appendix ESG highlights 2025 Proportion of women We are committed to the 69% UN Global Compact Corporate Responsibility in workforce Initiative and its 47% 0.1% principles in the areas of Customer complaint human rights, labor, in management rate environment and anti- corruption 16% 64% reduction Sh
Slide 19: ESG highlights 2025 (Nov 2025)
Appendix ESG highlights 2025 (Nov 2025) 0 62 100 Exceeds the industry benchmark D– C A+ Top 15% in the Industry CCC AA AAA Top 43% in the Industry 0 34 100 Top 50% universe ranking 100 0 41 100 Top 13% in the Industry 100 15.4 0 Top 9% in the Industry (low risk) Source: Reports of respective organiz
Slide 20: Successful Share Buyback Offer
Financial overview Successful Share Buyback Offer • Offer Share buyback: Up to 1,000,000 bearer shares of current share Capital: €25,505,723 (approx. 3.92% ) • Offer price per share: €12.50 (Approx. +9.3% premium over the 5-day XETRA average closing price) • Authorization: Granted by the AGM on June
Slide 21: Q3 2025 - Revenue growth driven by Pharmaceutical Supply
Appendix Q3 2025 - Revenue growth driven by Pharmaceutical Supply YoY Revenue in €m Q3 24 Organic Inorganic Q3 25 Comments Pharmaceutical Supply (PS) 403.3 36.1 439.4 • Organic growth 9.3%: a result of strong PS revenue increase and also Patient-Specific Therapies (PST) 54.1 1.7 55.8 contribution of
Slide 22: Q3 2025 - EBITDA pre at strong level of Q3 2024
Appendix Q3 2025 - EBITDA pre at strong level of Q3 2024 YoY EBITDA pre1 in €m Q3 24 Organic Inorganic Q3 25 Comments Pharmaceutical Supply (PS) 14.2 -1.8 12.4 • Organic growth by IB and PST • Decrease by PS Patient-Specific Therapies (PST) 5.9 0.2 6.1 International Business (IB) 7.1 0.7 0.4 8.2 Ser
Slide 23: Key figures (1/2)
Appendix Key figures (1/2) in € thousand 9M 2025 9M 2024 ∆ in % Q3 2025 Q3 2024 ∆ in % Revenue 1,529,997 1,400,505 9.2% 538,285 493,244 9.1% Pharmaceutical Supply 1,239,476 1,191,224 4.1% 439,366 403,294 8.9% Patient-Specific Therapies 166,017 161,574 2.7% 55,789 54,057 3.2% International 124,151 47
Slide 24: Key figures (2/2)
Appendix Key figures (2/2) in € thousand 9M 2025 9M 2024 ∆ in % Q3 2025 Q3 2024 ∆ in % Earnings per share (in €) Undiluted 0.79 0.43 84.0% 0.29 0.16 84.2% Diluted 0.79 0.43 84.0% 0.29 0.16 84.2% Adjusted 2 1.50 1.19 25.8% 0.52 0.48 9.0% Investments (CAPEX) -4,716 -3,557 32.6% -1,832 -1,773 3.3% Cash
Slide 25: Q3 2025 – Strong financials
Appendix Q3 2025 – Strong financials Pharmaceutical Patient-specific International Services IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' consolidation YoY in € million Q3 25 Q3 24 Q3 25 Q3 24 Q3 25 Q3 24 Q3 25 Q3 24 Q3 25 Q3 24 Q3 25 Q3 24 Segment revenue – extern. 439.4 403.3 55.8 54.1 43.0
Slide 26: The Medios share Shareholder Structure
Appendix The Medios share Shareholder Structure 65.2% Free float1 Basic Information • 6.4% Janus Henderson • 5.1% Paladin Asset Management • 4.7% SEB Investment Share Capital €25,505,723 • 3.9% Treasury shares2 • 3.3% Axxion No. of shares 25,505,723 Free float 19.7% Martin Hesse3 Share class No-par
Slide 27: Total target remuneration Remuneration System for the Executive Board
Appendix Remuneration System for the Total target remuneration Executive Board ESG Compensation structure of the total target remuneration Non-performance related fixed remuneration 28 – 35% Performance related remuneration 65 – 72% 1. Annual Short-Term-Incentive (STI) (target: 100%) 28 – 35%, STI t
Slide 28: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 Claudia.Nickolaus@medios.group
Slide 29: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 30: Q3/9M 2025 Results
Q3/9M 2025 Results Matthias Gaertner, CEO Falk Neukirch, CFO November 11, 2025